Discover trends, market shifts, and competitive outlooks for the chronic hepatitis b industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Are the Key Projections for the CAGR of the Chronic Hepatitis B Market Size From 2025 to 2034?

The market size of chronic hepatitis B has been witnessing consistent growth in the previous years. The growth is projected to continue, increasing from $3.77 billion in 2024 to $3.94 billion in 2025 with a compound annual growth rate (CAGR) of 4.5%. The expansion during the historical period is credited to advancements in antiviral therapy, heightened initiatives by the government and NGOs, betterment in diagnostic methodologies, an elevated occurrence of HIV, and a rise in consciousness.

Predictions for the chronic hepatitis B market size suggest a stable augment in the upcoming years, with projections to rise to $4.65 billion in 2029 at a 4.2% compound annual growth rate (CAGR). This anticipated boost during the forecast period can be credited to growth in developing markets, favorable governmental policies and funding, better diagnostic and screening methodologies, an upward trend in healthcare expenditure, an increase in strategic alliances and partnerships, an escalating elderly population, and public awareness initiatives. Significant forecast period trends encompass a move towards curative therapies, advancing in emerging markets, improved diagnostics and screening, cooperative initiatives and collaborations, with a patient-focused care approach.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Hepatitis B Market?

The chronic hepatitis B virus market is forecasted to grow due to the high incidence of the disease. Hepatitis B, a liver sickness caused by hepatitis B virus (HBV), can be prevented via vaccination. The surge in hepatitis B infection rates can be attributed to various factors, particularly the inadequate vaccination coverage in low- and middle-income countries, which leads to greater transmission rates as many remain unprotected. The escalation in infection rates could boost the demand for diagnostic tests and treatments for hepatitis B. For example, a report by Centers for Disease Control and Prevention (CDC), a U.S. government agency, in June 2024 stated that increasing the global hepatitis B vaccination coverage to 90% and ensuring 80% have access to treatment could avert 26 million new infections and 9 million deaths from hepatitis B between the years 2022 to 2050. In 2022 alone, there were about 1.2 million new cases of hepatitis B virus (HBV) infection. So, the high occurrence of hepatitis B infection augurs a positive outlook for the growth of the chronic hepatitis B virus market.

Which Key Market Segments Comprise the Chronic Hepatitis B Market and Drive Its Revenue Growth?

The chronic hepatitis B market covered in this report is segmented –

1) By Drug Class: Antivirals, Immune Modulators

2) By Gender: Male, Female

3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)

2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp

Which Areas Are Leading Regions in the Chronic Hepatitis B Market Expansion Across the Globe?

North America was the largest region in the chronic hepatitis B market in 2023. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Chronic Hepatitis B Market?

Leading firms in the chronic hepatitis B market are prioritizing technological innovation, particularly in the development of groundbreaking antiviral treatments. Novel antiviral therapies, like bepirovirsen for chronic hepatitis B, are revolutionary drugs designed to combat viral infections, including those where resistance is an issue. These medications work by obstructing virus replication and utilizing cutting-edge delivery systems, and are subject to ongoing clinical trials to confirm their safety and efficacy. For example, in February 2024, UK-based global pharmaceutical and biotech entity, GSK plc, received Fast Track designation by the U.S. FDA for bepirovirsen, a trial antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B. Bepirovirsen works by targeting and breaking down the hepatitis B virus’s RNA, potentially enabling the immune system to regain dominance over the infection. This drug has shown encouraging results in Phase IIb trials especially in B-Clear and B-Sure tests, demonstrating its power in reducing the levels of hepatitis B surface antigen (HBsAg) and achieving consistent viral suppression.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

How Is the Chronic Hepatitis B Market Conceptually Defined?

Chronic hepatitis B is a long-term infection with the hepatitis B virus (HBV) lasting over six months, potentially leading to severe liver damage, liver failure, or liver cancer. It is often asymptomatic for years but can be detected through blood tests and managed with antiviral medications and regular monitoring.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17112

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model